智通财经APP获悉，大摩发布研究报告称，维持海普瑞(09989)“增持”评级，对其作风险回报更新，目标价由11.4港元下调6.1%至10.7港元。集团公布2022年初步盈利后，该行下调对其2023-30年盈利预测4%至5%，当中考虑到活性药物成分(API，active pharmaceutical ingredient)产品销售下降及毛利率较低。
大摩：维持海普瑞(09989)“增持”评级 目标价降至10.7港元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.